616 related articles for article (PubMed ID: 31651562)
21. COVID-19 and treating incarcerated populations for opioid use disorder.
Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
[TBL] [Abstract][Full Text] [Related]
22. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.
Andraka-Christou B; Totaram R; Randall-Kosich O
Subst Abus; 2022; 43(1):415-424. PubMed ID: 34214400
[No Abstract] [Full Text] [Related]
23. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
[No Abstract] [Full Text] [Related]
24. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
[TBL] [Abstract][Full Text] [Related]
25. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Madden EF; Prevedel S; Light T; Sulzer SH
Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
[TBL] [Abstract][Full Text] [Related]
26. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
27. Naltrexone Compared With Buprenorphine or Methadone in Pregnancy: A Systematic Review.
Atluru S; Bruehlman AK; Vaughn P; Schauberger CW; Smid MC
Obstet Gynecol; 2024 Mar; 143(3):403-410. PubMed ID: 38227945
[TBL] [Abstract][Full Text] [Related]
28. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
McCann NC; LaRochelle MR; Morgan JR
J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
[TBL] [Abstract][Full Text] [Related]
29. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
31. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
32. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
[TBL] [Abstract][Full Text] [Related]
33. Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Will J; Abare M; Olson M; Chyorny A; Wilhelm-Leen E
J Subst Abuse Treat; 2022 Oct; 141():108838. PubMed ID: 35868162
[TBL] [Abstract][Full Text] [Related]
34. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
Nayak SM; Huhn AS; Bergeria CL; Strain EC; Dunn KE
Drug Alcohol Depend; 2021 Apr; 221():108649. PubMed ID: 33640679
[TBL] [Abstract][Full Text] [Related]
35. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Pilarinos A; Bromberg DJ; Karamouzian M
JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
[TBL] [Abstract][Full Text] [Related]
36. Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Pasman E; Lee G; Kollin R; Rodriguez B; Agius E; Madden EF; Resko SM
Subst Use Misuse; 2022; 57(12):1828-1836. PubMed ID: 36041008
[No Abstract] [Full Text] [Related]
37. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
38. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
39. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
[TBL] [Abstract][Full Text] [Related]
40. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
